Danske Bank A S Takes Position in Illumina, Inc. $ILMN

Danske Bank A S purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 57,809 shares of the life sciences company’s stock, valued at approximately $10,165,000.

A number of other hedge funds also recently bought and sold shares of ILMN. HighPoint Advisor Group LLC grew its position in Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares during the period. Elevation Wealth Partners LLC lifted its position in Illumina by 52.5% during the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares in the last quarter. Meeder Advisory Services Inc. grew its holdings in Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares during the period. Toronto Dominion Bank grew its holdings in Illumina by 0.3% during the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after purchasing an additional 92 shares during the period. Finally, Panagora Asset Management Inc. increased its position in Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after buying an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Insider Buying and Selling

In other Illumina news, Director Keith A. Meister sold 299,336 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the sale, the director directly owned 1,409,851 shares in the company, valued at $307,291,123.96. This represents a 17.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 2,095,958 shares of company stock valued at $401,720,974. 2.90% of the stock is currently owned by company insiders.

Illumina Trading Up 2.9%

ILMN stock opened at $219.40 on Friday. The firm has a fifty day moving average price of $188.01 and a 200 day moving average price of $152.44. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $220.43. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm has a market cap of $33.13 billion, a PE ratio of 40.93, a price-to-earnings-growth ratio of 3.00 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the firm earned $1.19 earnings per share. Illumina’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ILMN. Evercore restated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Leerink Partners upped their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a report on Wednesday, August 5th. Finally, Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.